Toggle menu

NOVEL Study

Start date:
April 2019
End date:
April 2021
Co-ordinated by:
LumiraDx
Main trial site:
Royal Infirmary Edinburgh

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Primary Objective: evaluation of diagnostic platform with biomarkers useful in emergency settings.

Sample: Patients over 18 years old presenting to the Emergency Department with mainly symptoms of cardiovascular conditions.

Trial Design: Prospective observational (cohort) feasibility study

Chief Investigator

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Caroline Blackstock

AMU Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Rachel O'Brien

Lead Research Nurse

Fiona McCurrach

Senior Research Nurse

Alison Williams

Senior Research Nurse

Clare Moceivei

Senior Research Nurse

Nicky Freeman

Senior Research Nurse

Kayleigh Craig

Research Nurse

Fraser Craig

Clinical Trial Assistant

Claire Cheyne

Research Nurse- Bank Staff

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

Prospective multicentre observational study conducted over one calendar month in 2019, with the aim of describing the epidemiology of non-trauma related headache in adults presenting to emergency departments including investigations, treatments and outcome.

This will include adult patients presenting to the ED with non-trauma-related headache as their primary complaint.

Read more

HEAD Study

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.